These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34125445)

  • 1. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
    Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer.
    Nunes-Xavier CE; Emaldi M; Guldvik IJ; Ramberg H; Taskén KA; Mælandsmo GM; Fodstad Ø; Llarena R; Pulido R; López JI
    Pathol Res Pract; 2023 Jan; 241():154243. PubMed ID: 36481650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
    Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High B7-H3 expression is linked to increased risk of prostate cancer progression.
    Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
    Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 7. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
    Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
    Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer.
    Kang N; Xue H; Lin YY; Dong X; Classen A; Wu R; Jin Y; Lin D; Volik S; Ong C; Gleave M; Collins C; Wang Y
    Cancer Gene Ther; 2023 Oct; 30(10):1382-1389. PubMed ID: 37452083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
    Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
    Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
    Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
    Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
    Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer.
    Shi X; Day A; Bergom HE; Tape S; Baca SC; Sychev ZE; Larson G; Bozicevich A; Drake JM; Zorko N; Wang J; Ryan CJ; Antonarakis ES; Hwang J
    NPJ Precis Oncol; 2022 Nov; 6(1):80. PubMed ID: 36323882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
    Gevensleben H; Dietrich D; Golletz C; Steiner S; Jung M; Thiesler T; Majores M; Stein J; Uhl B; Müller S; Ellinger J; Stephan C; Jung K; Brossart P; Kristiansen G
    Clin Cancer Res; 2016 Apr; 22(8):1969-77. PubMed ID: 26573597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
    Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
    Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinical significance of VISTA, B7-H3, and PD-L1 in glioma.
    Wang LC; Wang YL; He B; Zheng YJ; Yu HC; Liu ZY; Fan RR; Zan X; Liang RC; Wu ZP; Tang X; Wang GQ; Xu JG; Zhou LX
    Clin Immunol; 2022 Dec; 245():109178. PubMed ID: 36368642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.